{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T06:12:14Z","timestamp":1757311934466},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2005,11,1]],"date-time":"2005-11-01T00:00:00Z","timestamp":1130803200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Internist"],"published-print":{"date-parts":[[2005,11]]},"DOI":"10.1007\/s00108-005-1490-x","type":"journal-article","created":{"date-parts":[[2005,9,8]],"date-time":"2005-09-08T12:31:55Z","timestamp":1126182715000},"page":"1198-1206","source":"Crossref","is-referenced-by-count":11,"title":["Lipidsenker- und andere toxische Myopathien"],"prefix":"10.1007","volume":"46","author":[{"given":"B. G. H.","family":"Schoser","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Pongratz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"1490_CR1","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0376-8716(00)00219-2","volume":"63","author":"Preedy","year":"2001","unstructured":"Preedy VR, Paice A, Mantle D, Dhillon AS, Palmer TN, Peters TJ (2001) Alcoholic myopathy: biochemical mechanisms. Drug Alcohol Depend 63: 199\u2013205","journal-title":"Drug Alcohol Depend"},{"key":"1490_CR2","first-page":"23","volume":"57","author":"Owczarek","year":"2005","unstructured":"Owczarek J, Jasinska M, Orszulak-Michalak D (2005) Drug-induced myopathies. An overview of the possible mechanisms. Pharmacol Rep 57: 23\u201334","journal-title":"Pharmacol Rep"},{"key":"1490_CR3","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1002\/mus.10244","volume":"27","author":"Sieb","year":"2003","unstructured":"Sieb JP, Gillessen T (2003) Iatrogenic and toxic myopathies. Muscle Nerve 27: 142\u2013156","journal-title":"Muscle Nerve"},{"key":"1490_CR4","first-page":"24","volume":"56","author":"Kanda","year":"2001","unstructured":"Kanda F, Okuda S, Matsushita T, Takatani K, Kimura KI, Chihara K (2001) Steroid myopathy: pathogenesis and effects of growth hormone and insulin-like growth factor-I administration. Horm Res 56 [Suppl 1]: 24\u201328","journal-title":"Horm Res"},{"key":"1490_CR5","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/0091-6749(85)90708-0","volume":"76","author":"Bowyer","year":"1985","unstructured":"Bowyer SL, LaMothe MP, Hollister JR (1985) Steroid myopathy: incidence and detection in a population with asthma. J Allergy Clin Immunol 76: 234\u2013242","journal-title":"J Allergy Clin Immunol"},{"key":"1490_CR6","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1212\/WNL.48.5.1234","volume":"48","author":"Batchelor","year":"1997","unstructured":"Batchelor TT, Taylor LP, Thaler HT, Posner JB, DeAngelis LM (1997) Steroid myopathy in cancer patients. Neurology 48: 1234\u20131238","journal-title":"Neurology"},{"key":"1490_CR7","first-page":"E1157","volume":"263","author":"Falduto","year":"1992","unstructured":"Falduto MT, Young AP, Hickson RC (1992) Exercise interrupts ongoing glucocorticoid-induced muscle atrophy and glutamine synthetase induction. Am J Physiol 263: E1157\u20131163","journal-title":"Am J Physiol"},{"key":"1490_CR8","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1161\/01.CIR.0000066320.27195.B4","volume":"107","author":"Ford","year":"2003","unstructured":"Ford ES, Mokdad AH, Giles WH, Mensah GA (2003) Serum total cholesterol concentrations and awareness, treatment, and control of hypercholesterolemia among US adults; findings from the National Health and Nutrition Examination Survey. Circulation 107: 2185\u20132189","journal-title":"Circulation"},{"key":"1490_CR9","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1007\/s00115-004-1806-4","volume":"76","author":"Menge","year":"2005","unstructured":"Menge T, von B\u00fcding HC, Zamvil SS, Hartung HP, Kieseier BC, St\u00fcve O (2005) Statine zur Behandlung von Erkrankungen des zentralen Nervensystems. Eine Standortbestimmung aus Forschung und Klinik. Nervenarzt 76: 426\u2013437","journal-title":"Nervenarzt"},{"key":"1490_CR10","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1136\/bmj.323.7309.359","volume":"323","author":"Charatan","year":"2001","unstructured":"Charatan F (2001) Bayer decides to withdraw cholesterol lowering drug. BMJ 323: 359","journal-title":"BMJ"},{"key":"1490_CR11","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/00001648-200109000-00017","volume":"12","author":"Gaist","year":"2001","unstructured":"Gaist D, Rodriguez LA, Huerta C, Hallas J, Sindrup SH (2001) Lipid lowering drugs and risk of myopathy: a population-based follow-up study. Epidemiology 12: 565\u2013569","journal-title":"Epidemiology"},{"key":"1490_CR12","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1001\/jama.292.21.2585","volume":"292","author":"Graham","year":"2004","unstructured":"Graham DJ, Staffa JA, Shatin D et al. (2004) Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 292: 2585\u20132590","journal-title":"JAMA"},{"key":"1490_CR13","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.amjcard.2004.08.076","volume":"95","author":"Jones","year":"2005","unstructured":"Jones PH, Davidson MH (2005) Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am J Cardiol 95: 120\u2013122","journal-title":"Am J Cardiol"},{"key":"1490_CR14","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1001\/jama.289.13.1681","volume":"289","author":"Thompson","year":"2003","unstructured":"Thompson PD, Clarkson P, Karas RH (2003) Statin-associated myopathy. JAMA 289: 1681\u20131690","journal-title":"JAMA"},{"key":"1490_CR15","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1023\/B:CARD.0000015861.26111.ab","volume":"17","author":"Franc","year":"2004","unstructured":"Franc S, Dejager S, Bruckert E, Chauvenet M, Giral P, Turpin G (2004) A comprehensive description of muscle symptoms associated with lipid-lowering drugs. Cardiovasc Drugs Ther 17: 459\u2013465","journal-title":"Cardiovasc Drugs Ther"},{"key":"1490_CR16","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s00115-002-1445-6","volume":"74","author":"Finsterer","year":"2003","unstructured":"Finsterer J (2003) Fibrat-\/Statin-Myopathie. Nervenarzt 74: 115\u2013122","journal-title":"Nervenarzt"},{"key":"1490_CR17","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1007\/s00115-004-1837-x","volume":"76","author":"K","year":"2005","unstructured":"K\u00f6ller H, Neuhaus O, Schroeter M, Hartung HP (2005) Myopathien unter Therapie mit Lipidsenkern. Nervenarzt 76: 212\u2013217","journal-title":"Nervenarzt"},{"key":"1490_CR18","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/mus.20127","volume":"30","author":"Vasconcelos","year":"2004","unstructured":"Vasconcelos OM, Campbell WW (2004) Dermatomyositis-like syndrome and HMG-CoA reductase inhibitor (statin) intake. Muscle Nerve 30: 803\u2013807","journal-title":"Muscle Nerve"},{"key":"1490_CR19","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1212\/01.WNL.0000145708.03876.C3","volume":"63","author":"Cartwright","year":"2004","unstructured":"Cartwright MS, Jeffery DR, Nuss GR, Donofrio PD (2004) Statin-associated exacerbation of myasthenia gravis. Neurology 63: 2188","journal-title":"Neurology"},{"key":"1490_CR20","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1592\/phco.24.13.1194.38084","volume":"24","author":"Chong","year":"2004","unstructured":"Chong PH, Boskovich A, Stevkovic N, Bartt RE (2004) Statin-induced peripheral neuropathy: review of the literature. Pharmacotherapy 24: 1194\u20131203","journal-title":"Pharmacotherapy"},{"key":"1490_CR21","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.nmd.2003.12.004","volume":"14","author":"Taylor","year":"2004","unstructured":"Taylor RW, Schaefer AM, Barron MJ, McFarland R, Turnbull DM (2004) The diagnosis of mitochondrial muscle disease. Neuromuscul Disord 14: 237\u2013245","journal-title":"Neuromuscul Disord"},{"key":"1490_CR22","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/biof.5520180212","volume":"18","author":"Langsjoen","year":"2003","unstructured":"Langsjoen PH, Langsjoen AM (2003) The clinical use of HMG CoA-reductase inhibitors and the associacited depletion of coenzyme Q10. A review of animal and human publications. Biofactors 18: 101\u2013111","journal-title":"Biofactors"},{"key":"1490_CR23","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1001\/archneur.62.2.317","volume":"62","author":"Lalani","year":"2005","unstructured":"Lalani SR, Vladutiu GD, Plunkett K, Lotze TE, Adesina AM, Scaglia F (2005) Isolated mitochondrial myopathy associated with muscle coenzyme Q10 deficiency. Arch Neurol 62: 317\u2013320","journal-title":"Arch Neurol"},{"key":"1490_CR24","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.taap.2004.04.010","volume":"200","author":"Johnson","year":"2004","unstructured":"Johnson TE, Zhang X, Bleicher KB, Dysart G, Loughlin AF, Schaefer WH, Umbenhauer DR (2004) Statins induce apoptosis in rat and human myotube cultures by inhibiting protein geranylgeranylation but not ubiquinone. Toxicol Appl Pharmacol 200: 237\u2013250","journal-title":"Toxicol Appl Pharmacol"},{"key":"1490_CR25","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S1388-1981(00)00150-5","volume":"29","author":"Fielding","year":"2000","unstructured":"Fielding C, Fielding PE (2000) Cholesterol and caveolae: structural and functional relationships. Biochem Biophys Acta 29: 210\u2013222","journal-title":"Biochem Biophys Acta"},{"key":"1490_CR26","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/90050","volume":"28","author":"Betz","year":"2001","unstructured":"Betz RC, Schoser BGH, Kasper D et al. (2001) Mutations in CAV-3 cause mechanical hyperirritability of skeletal muscle in rippling muscle disease. Nat Genet 28: 218\u2013219","journal-title":"Nat Genet"},{"key":"1490_CR27","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S0021-9150(00)00597-9","volume":"155","author":"Sumi","year":"2001","unstructured":"Sumi D, Hayashi T, Thakur NK et al. (2001) A HMG-CoA reductase inhibitor possesses a potent antiatherosclerotic effect other than serum lipid lowering effects \u2014 the relevance of endothelial nitric oxide synthase and superoxide anion scavenging action. Atheriosclerosis 155: 347\u2013357","journal-title":"Atheriosclerosis"},{"key":"1490_CR28","doi-asserted-by":"crossref","first-page":"F29","DOI":"10.1083\/jcb.152.5.F29","volume":"152","author":"van Meer","year":"2001","unstructured":"van Meer G (2001) Caveolin, cholesterol, and lipid droplets? J Cell Biol 152: F29\u201334","journal-title":"J Cell Biol"},{"key":"1490_CR29","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.amjmed.2003.10.033","volume":"116","author":"Rosenson","year":"2004","unstructured":"Rosenson RS (2004) Current overview of statin-induced myopathy. Am J Med 116: 408\u2013416","journal-title":"Am J Med"},{"key":"1490_CR30","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1161\/01.str.0000034125.94759.41","volume":"33","author":"Pasternak","year":"2002","unstructured":"Pasternak RC, Smith SC, Bairey-Merz JI, Grundy SM, Cleeman JI, Lenfant C (2002) ACC\/AHA\/NHLBI clinical advisory on the use and safety of statins. Stroke 33: 2337\u20132341","journal-title":"Stroke"},{"key":"1490_CR31","unstructured":"Arzneimittelkommission der deutschen \u00c4rzteschaft (2004) Aus der UAW-Datenbank: Myopathien bzw. Leberreaktionen unter Ezetimib. Dtsch \u00c4rztebl 101: A959"}],"container-title":["Der Internist"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-005-1490-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00108-005-1490-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-005-1490-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T04:11:33Z","timestamp":1558584693000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00108-005-1490-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,11]]},"references-count":31,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2005,11]]}},"alternative-id":["1490"],"URL":"https:\/\/doi.org\/10.1007\/s00108-005-1490-x","relation":{},"ISSN":["0020-9554","1432-1289"],"issn-type":[{"value":"0020-9554","type":"print"},{"value":"1432-1289","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,11]]}}}